Skip to main content
Premium Trial:

Request an Annual Quote

Courtagen Raises $6.3M

NEW YORK (GenomeWeb) – Courtagen Life Sciences has raised about $6.3 million, the genetic testing firm disclosed in a document filed with the US Securities and Exchange Commission this week.

Courtagen did not disclose the identity of the investors or say how proceeds will be used. It did not respond to requests seeking clarification.

The Woburn, Mass.-based company develops tests for mitochondrial disorders, epilepsy and seizure disorders, Autism Spectrum Disorder, and other conditions based on next-generation sequencing technology. This week, it announced a deal with Seizure Tracker aimed at epilepsy.

In May it and Sciencewerke reached an agreement for the distribution of Courtagen's clinical NGS tests, and the month before that Courtagen and Connecticut Children's Medical Center said they would collaborate to identify alterations in genes associated with ASD.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.